India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is reportedly working on an Omicron-specific vaccine that is likely to be ready in a couple of months. The potential vaccine might undergo a small trial in India before being exported as a booster shot or a standalone vaccine.

The apparent mRNA vaccine, produced specially to counter the recent Omicron variant, will be tested on humans first to know its efficiency and immunogenic soon.

The company had issued a press statement regarding the vaccine back in September 2021. It stated that the DCGI (Drug Controller General of India) had already approved the Phase II and Phase III study for the mRNA-based COVID-19 vaccine.